{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:31:17Z","timestamp":1780489877325,"version":"3.54.1"},"reference-count":133,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.ccl.2008.01.001","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T00:24:56Z","timestamp":1221092696000},"page":"59-72","source":"Crossref","is-referenced-by-count":16,"title":["Traditional and Novel Approaches to Management of Heart Failure: Successes and Failures"],"prefix":"10.1016","volume":"26","author":[{"given":"Inder S.","family":"Anand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viorel G.","family":"Florea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccl.2008.01.001_bib1","series-title":"Heart failure: companion to Braunwald's heart disease","first-page":"229","article-title":"Alterations in ventricular structure: role of left ventricular remodeling","author":"Anand","year":"2002"},{"key":"10.1016\/j.ccl.2008.01.001_bib2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.CIR.85.2.790","article-title":"Adrenergic effects on the biology of the adult mammalian cardiocyte","volume":"85","author":"Mann","year":"1992","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ccl.2008.01.001_bib3","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/01.RES.69.5.1185","article-title":"Cardiac myocyte necrosis induced by angiotensin II","volume":"69","author":"Tan","year":"1991","journal-title":"Circ Res"},{"issue":"11","key":"10.1016\/j.ccl.2008.01.001_bib4","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/01.RES.0000043825.01705.1B","article-title":"Inflammatory mediators and the failing heart: past, present, and the foreseeable future","volume":"91","author":"Mann","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.ccl.2008.01.001_bib5","series-title":"Heart hypertrophy and failure","first-page":"487","article-title":"Neurohormonal responses in congestive heart failure: effect of ACE inhibitors in randomized controlled clinical trials","author":"Anand","year":"1996"},{"key":"10.1016\/j.ccl.2008.01.001_bib6","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1161\/01.CIR.0000054164.99881.00","article-title":"Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in Val-HeF","volume":"107","author":"Anand","year":"2003","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.ccl.2008.01.001_bib7","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ccl.2008.01.001_bib8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators","volume":"325","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2008.01.001_bib9","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"The MERIT-HF Investigators. Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ccl.2008.01.001_bib10","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ccl.2008.01.001_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ccl.2008.01.001_bib12","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ccl.2008.01.001_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cardfail.2004.05.006","article-title":"Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study","volume":"11","author":"Packer","year":"2005","journal-title":"J Card Fail"},{"issue":"8","key":"10.1016\/j.ccl.2008.01.001_bib14","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ccl.2008.01.001_bib15","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"issue":"9431","key":"10.1016\/j.ccl.2008.01.001_bib16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(04)16723-8","article-title":"Long-term Effects of Darusentan on LV Remodeling and Clinical Outcomes\u2014The EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH)","volume":"364","author":"Anand","year":"2004","journal-title":"Lancet"},{"issue":"9146","key":"10.1016\/j.ccl.2008.01.001_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","author":"The CIBIS II Investigators","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ccl.2008.01.001_bib18","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/0735-1097(94)00543-Y","article-title":"Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade","volume":"25","author":"Hall","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2008.01.001_bib19","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/0735-1097(92)90337-M","article-title":"Application of cine nuclear magnetic resonance imaging for sequential evaluation of response to angiotensin-converting enzyme inhibitor therapy in dilated cardiomyopathy","volume":"19","author":"Doherty","year":"1992","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.ccl.2008.01.001_bib20","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJM198409273111303","article-title":"Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure","volume":"311","author":"Cohn","year":"1984","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ccl.2008.01.001_bib21","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators","volume":"94","author":"Bristow","year":"1996","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.ccl.2008.01.001_bib22","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1161\/01.CIR.0000014212.04920.62","article-title":"Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure","volume":"105","author":"Swedberg","year":"2002","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ccl.2008.01.001_bib23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1388-9842(03)00163-6","article-title":"Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)","volume":"5","author":"Cohn","year":"2003","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"10.1016\/j.ccl.2008.01.001_bib24","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJM200105313442202","article-title":"A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure","volume":"344","author":"The BEST Investigators","year":"2001","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ccl.2008.01.001_bib25","first-page":"II-755","article-title":"Sympatholytic effect of bucindolol adversely affected survival, and was disproportionately observed in the class IV subgroup of BEST","volume":"104","author":"Bristow","year":"2001","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ccl.2008.01.001_bib26","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"The SOLVD Investigators","year":"1992","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ccl.2008.01.001_bib27","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"issue":"8875","key":"10.1016\/j.ccl.2008.01.001_bib28","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","author":"The AIRE Study Investigators","year":"1993","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ccl.2008.01.001_bib29","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"Kober","year":"1995","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ccl.2008.01.001_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/01.CIR.89.1.68","article-title":"Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril","volume":"89","author":"St. John Sutton","year":"1994","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ccl.2008.01.001_bib31","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1161\/01.CIR.91.10.2573","article-title":"Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy","volume":"91","author":"Greenberg","year":"1995","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.ccl.2008.01.001_bib32","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ccl.2008.01.001_bib33","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/S0735-1097(00)01025-1","article-title":"Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group","volume":"36","author":"Nanas","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ccl.2008.01.001_bib34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0735-1097(01)01714-4","article-title":"Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure","volume":"39","author":"Tang","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ccl.2008.01.001_bib35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1440-1681.1992.tb00503.x","article-title":"Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects","volume":"19","author":"Kawamura","year":"1992","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"8","key":"10.1016\/j.ccl.2008.01.001_bib36","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.CIR.101.8.844","article-title":"Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure","volume":"101","author":"Jorde","year":"2000","journal-title":"Circulation"},{"issue":"9386","key":"10.1016\/j.ccl.2008.01.001_bib37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"issue":"9386","key":"10.1016\/j.ccl.2008.01.001_bib38","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"issue":"9386","key":"10.1016\/j.ccl.2008.01.001_bib39","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"issue":"9386","key":"10.1016\/j.ccl.2008.01.001_bib40","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ccl.2008.01.001_bib41","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ccl.2008.01.001_bib42","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0735-1097(02)02304-5","article-title":"Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors","volume":"40","author":"Maggioni","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ccl.2008.01.001_bib43","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(02)02063-6","article-title":"Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study","volume":"40","author":"Wong","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2008.01.001_bib44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/cvr\/27.3.341","article-title":"Myocardial fibrosis: functional significance and regulatory factors","volume":"27","author":"Weber","year":"1993","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.ccl.2008.01.001_bib45","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","article-title":"Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism","volume":"25","author":"Brilla","year":"1993","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"10.1016\/j.ccl.2008.01.001_bib46","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1172\/JCI117269","article-title":"Mineralocorticoids, hypertension, and cardiac fibrosis","volume":"93","author":"Young","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ccl.2008.01.001_bib47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/archinte.1964.00280090017004","article-title":"Aldosterone and the edema of congestive heart failure","volume":"113","author":"Sanders","year":"1964","journal-title":"Arch Intern Med"},{"issue":"14","key":"10.1016\/j.ccl.2008.01.001_bib48","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ccl.2008.01.001_bib49","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"Hayashi","year":"2003","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ccl.2008.01.001_bib50","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/01.RES.87.10.840","article-title":"Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress","volume":"87","author":"Cai","year":"2000","journal-title":"Circ Res"},{"issue":"23","key":"10.1016\/j.ccl.2008.01.001_bib51","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1161\/01.CIR.99.23.2972","article-title":"Nitric oxide synthases in the failing human heart: a doubled-edged sword?","volume":"99","author":"Drexler","year":"1999","journal-title":"Circulation"},{"issue":"2 Pt 2","key":"10.1016\/j.ccl.2008.01.001_bib52","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/hy02t2.102796","article-title":"Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure","volume":"39","author":"Liu","year":"2002","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.ccl.2008.01.001_bib53","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1073\/pnas.0837428100","article-title":"Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice","volume":"100","author":"Jones","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.ccl.2008.01.001_bib54","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/hc3601.094298","article-title":"Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice","volume":"104","author":"Scherrer-Crosbie","year":"2001","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.ccl.2008.01.001_bib55","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1161\/01.CIR.0000066283.13253.78","article-title":"Functional consequences of endothelial nitric oxide synthase uncoupling in congestive cardiac failure","volume":"107","author":"Dixon","year":"2003","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.ccl.2008.01.001_bib56","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/0002-9149(92)90710-G","article-title":"Endothelial function in chronic congestive heart failure","volume":"69","author":"Drexler","year":"1992","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.ccl.2008.01.001_bib57","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1161\/01.CIR.84.4.1589","article-title":"Endothelium-dependent vasodilation is attenuated in patients with heart failure","volume":"84","author":"Kubo","year":"1991","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccl.2008.01.001_bib58","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/01.CIR.100.3.216","article-title":"Increased superoxide in heart failure: a biochemical baroreflex gone awry","volume":"100","author":"Munzel","year":"1999","journal-title":"Circulation"},{"issue":"1 Pt 1","key":"10.1016\/j.ccl.2008.01.001_bib59","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1161\/01.HYP.30.1.50","article-title":"Basal release of nitric oxide is decreased in the coronary circulation in patients with heart failure","volume":"30","author":"Mohri","year":"1997","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ccl.2008.01.001_bib60","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.CIR.97.2.161","article-title":"Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness","volume":"97","author":"Hare","year":"1998","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.ccl.2008.01.001_bib61","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ccl.2008.01.001_bib62","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ccl.2008.01.001_bib63","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.cardfail.2007.03.001","article-title":"Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT","volume":"13","author":"Cohn","year":"2007","journal-title":"J Card Fail"},{"issue":"Suppl 6","key":"10.1016\/j.ccl.2008.01.001_bib64","first-page":"VI17","article-title":"Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure","volume":"87","author":"Cintron","year":"1993","journal-title":"Circulation"},{"issue":"6163","key":"10.1016\/j.ccl.2008.01.001_bib65","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"issue":"8926","key":"10.1016\/j.ccl.2008.01.001_bib66","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0140-6736(94)92827-4","article-title":"Contribution of endogenous generation of endothelin-1 to basal vascular tone","volume":"344","author":"Haynes","year":"1994","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ccl.2008.01.001_bib67","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/01.CIR.85.2.510","article-title":"Elevated endothelin-1 in heart failure and loss of normal response to postural change","volume":"85","author":"Stewart","year":"1992","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccl.2008.01.001_bib68","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/01.CIR.85.4.1374","article-title":"Plasma endothelin in chronic heart failure","volume":"85","author":"McMurray","year":"1992","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccl.2008.01.001_bib69","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/01.CIR.89.4.1573","article-title":"Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction","volume":"89","author":"Omland","year":"1994","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.ccl.2008.01.001_bib70","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1097\/00005344-199800001-00120","article-title":"Expression of endothelin-1 and endothelin-converting enzyme-1 mRNAs and proteins in failing human hearts","volume":"31","author":"Fukuchi","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6607","key":"10.1016\/j.ccl.2008.01.001_bib71","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/384353a0","article-title":"Inhibition of myocardial endothelin pathway improves long-term survival in heart failure","volume":"384","author":"Sakai","year":"1996","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.ccl.2008.01.001_bib72","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/01.CIR.98.21.2262","article-title":"Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure","volume":"98","author":"Sutsch","year":"1998","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.ccl.2008.01.001_bib73","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/01.CIR.0000038497.80095.E1","article-title":"Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT)","volume":"106","author":"Luscher","year":"2002","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ccl.2008.01.001_bib74","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0735-1097(97)00296-9","article-title":"Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure","volume":"30","author":"Wada","year":"1997","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ccl.2008.01.001_bib75","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/01.CIR.100.9.999","article-title":"Mechanisms and models in heart failure: a combinatorial approach","volume":"100","author":"Mann","year":"1999","journal-title":"Circulation"},{"issue":"2 Pt 2","key":"10.1016\/j.ccl.2008.01.001_bib76","first-page":"H517","article-title":"Soluble TNF binding proteins modulate the negative inotropic properties of TNF-alpha in vitro","volume":"268","author":"Kapadia","year":"1995","journal-title":"Am J Physiol"},{"issue":"25","key":"10.1016\/j.ccl.2008.01.001_bib77","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1161\/01.CIR.99.25.3224","article-title":"Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure","volume":"99","author":"Deswal","year":"1999","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ccl.2008.01.001_bib78","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.CIR.103.8.1044","article-title":"Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure","volume":"103","author":"Bozkurt","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2008.01.001_bib79","article-title":"RENEWAL trial: no improvement in CHF with etanercept","author":"Wood","year":"2002","journal-title":"HeartWire News"},{"issue":"13","key":"10.1016\/j.ccl.2008.01.001_bib80","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2008.01.001_bib81","doi-asserted-by":"crossref","unstructured":"Packer M, Chung E, Batra S, et\u00a0al. Randomized placebo-controlled dose-ranging trial of infliximab, a monoclonal antibody to tumor necrosis factor-alpha, in moderate to severe heart failure. Presented at the Annual Meeting of HFSA. Boca Raton, FL, September 25, 2002.","DOI":"10.1161\/01.CIR.0000077913.60364.D2"},{"issue":"5","key":"10.1016\/j.ccl.2008.01.001_bib82","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0828-282X(07)70770-5","article-title":"A\u00a0study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design","volume":"23","author":"Torre-Amione","year":"2007","journal-title":"Can J Cardiol"},{"issue":"9608","key":"10.1016\/j.ccl.2008.01.001_bib83","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(08)60134-8","article-title":"Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM) trial: a placebo-controlled randomised trial","volume":"371","author":"Torre-Amione","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2008.01.001_bib84","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1161\/01.CIR.80.2.299","article-title":"Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure","volume":"80","author":"Anand","year":"1989","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ccl.2008.01.001_bib85","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2005.02.095","article-title":"Vasopressin antagonism in heart failure","volume":"46","author":"Goldsmith","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ccl.2008.01.001_bib86","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1210\/jc.2005-2287","article-title":"Efficacy and safety of oral conivaptan: a V1A\/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia","volume":"91","author":"Ghali","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"10.1016\/j.ccl.2008.01.001_bib87","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.ccl.2008.01.001_bib88","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.ccl.2008.01.001_bib89","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","article-title":"Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction","volume":"49","author":"Udelson","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.ccl.2008.01.001_bib90","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","article-title":"Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure","volume":"104","author":"Udelson","year":"2001","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccl.2008.01.001_bib91","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/01.CIR.85.3.942","article-title":"Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group","volume":"85","author":"Kubo","year":"1992","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.ccl.2008.01.001_bib92","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","article-title":"Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)","volume":"23","author":"Moiseyev","year":"2002","journal-title":"Eur Heart J"},{"issue":"9328","key":"10.1016\/j.ccl.2008.01.001_bib93","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ccl.2008.01.001_bib94","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ejheart.2004.04.014","article-title":"Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure","volume":"6","author":"Cleland","year":"2004","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"10.1016\/j.ccl.2008.01.001_bib95","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ccl.2008.01.001_bib96","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejheart.2005.12.003","article-title":"Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE","volume":"8","author":"Cleland","year":"2006","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.ccl.2008.01.001_bib97","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00392-005-0210-9","article-title":"Heart failure and statins\u2014why do we need a clinical trial?","volume":"94","author":"Bohm","year":"2005","journal-title":"Z Kardiol"},{"issue":"5","key":"10.1016\/j.ccl.2008.01.001_bib98","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/j.1523-1755.2005.00261.x","article-title":"Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors","volume":"67","author":"Urbich","year":"2005","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.ccl.2008.01.001_bib99","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.atherosclerosis.2004.10.009","article-title":"Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure","volume":"179","author":"Strey","year":"2005","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ccl.2008.01.001_bib100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.atherosclerosis.2004.08.037","article-title":"Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure","volume":"178","author":"Tousoulis","year":"2005","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.ccl.2008.01.001_bib101","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0735-1097(02)01854-5","article-title":"Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure","volume":"39","author":"Horwich","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.ccl.2008.01.001_bib102","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.jacc.2003.07.016","article-title":"The relationship between cholesterol and survival in patients with chronic heart failure","volume":"42","author":"Rauchhaus","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"9233","key":"10.1016\/j.ccl.2008.01.001_bib103","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0140-6736(00)02690-8","article-title":"The endotoxin-lipoprotein hypothesis","volume":"356","author":"Rauchhaus","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ccl.2008.01.001_bib104","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/archneur.61.6.889","article-title":"Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke","volume":"61","author":"Rundek","year":"2004","journal-title":"Arch Neurol"},{"issue":"9412","key":"10.1016\/j.ccl.2008.01.001_bib105","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(04)15739-5","article-title":"Selenoprotein synthesis and side-effects of statins","volume":"363","author":"Moosmann","year":"2004","journal-title":"Lancet"},{"issue":"23 Suppl 1","key":"10.1016\/j.ccl.2008.01.001_bib106","first-page":"III50","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.ccl.2008.01.001_bib107","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1001\/jama.296.17.2105","article-title":"Statin therapy and risks for death and hospitalization in chronic heart failure","volume":"296","author":"Go","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ccl.2008.01.001_bib108","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jacc.2003.07.049","article-title":"Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure","volume":"43","author":"Horwich","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ccl.2008.01.001_bib109","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijcard.2006.07.106","article-title":"Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT","volume":"119","author":"Krum","year":"2007","journal-title":"Int J Cardiol"},{"issue":"22","key":"10.1016\/j.ccl.2008.01.001_bib110","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ccl.2008.01.001_bib111","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ejheart.2004.03.001","article-title":"Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure","volume":"6","author":"Tavazzi","year":"2004","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.ccl.2008.01.001_bib112","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/heart.87.4.377","article-title":"Anaemia in chronic heart failure: what is its frequency in the UK and its underlying causes?","volume":"87","author":"Cromie","year":"2002","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.ccl.2008.01.001_bib113","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/01.CIR.0000052622.51963.FC","article-title":"Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure","volume":"107","author":"Ezekowitz","year":"2003","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ccl.2008.01.001_bib114","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1161\/CIRCULATIONAHA.104.512988","article-title":"Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT","volume":"112","author":"Anand","year":"2005","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ccl.2008.01.001_bib115","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archinte.165.11.1304","article-title":"Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers","volume":"165","author":"George","year":"2005","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.ccl.2008.01.001_bib116","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/0002-9149(94)90905-9","article-title":"Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles","volume":"74","author":"Volpe","year":"1994","journal-title":"Am J Cardiol"},{"issue":"16","key":"10.1016\/j.ccl.2008.01.001_bib117","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.103.16.2055","article-title":"Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST)","volume":"103","author":"Deswal","year":"2001","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ccl.2008.01.001_bib118","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/CIRCULATIONAHA.104.508465","article-title":"C-reactive protein in heart failure: prognostic value and the effect of valsartan","volume":"112","author":"Anand","year":"2005","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccl.2008.01.001_bib119","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1046\/j.1523-1755.1998.00084.x","article-title":"Role of cytokines in the response to erythropoietin in hemodialysis patients","volume":"54","author":"Goicoechea","year":"1998","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.ccl.2008.01.001_bib120","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/00007890-200108150-00035","article-title":"Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant reciepients: Prospective randomized study","volume":"72","author":"Alaattin","year":"2001","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.ccl.2008.01.001_bib121","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/ndt\/13.5.1206","article-title":"High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients","volume":"13","author":"Albitar","year":"1998","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.ccl.2008.01.001_bib122","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.ahj.2003.11.007","article-title":"Are hematinic deficiencies the cause of anemia in chronic heart failure?","volume":"147","author":"Witte","year":"2004","journal-title":"Am Heart J"},{"issue":"12","key":"10.1016\/j.ccl.2008.01.001_bib123","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.jacc.2006.08.034","article-title":"Etiology of anemia in patients with advanced heart failure","volume":"48","author":"Nanas","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ccl.2008.01.001_bib124","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/01.CIR.96.2.526","article-title":"Hormonal changes and catabolic\/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia","volume":"96","author":"Anker","year":"1997","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ccl.2008.01.001_bib125","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1161\/01.CIR.0000052623.16194.80","article-title":"Hemodilution is common in patients with advanced heart failure","volume":"107","author":"Androne","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ccl.2008.01.001_bib126","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/01.CIR.0000044914.42696.6A","article-title":"Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure","volume":"107","author":"Mancini","year":"2003","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ccl.2008.01.001_bib127","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0735-1097(00)00613-6","article-title":"The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations","volume":"35","author":"Silverberg","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ccl.2008.01.001_bib128","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0735-1097(01)01248-7","article-title":"The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study","volume":"37","author":"Silverberg","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ccl.2008.01.001_bib129","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.70.4.357","article-title":"Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones","volume":"70","author":"Anand","year":"1993","journal-title":"Br Heart J"},{"issue":"6","key":"10.1016\/j.ccl.2008.01.001_bib130","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/0735-1097(95)00007-Q","article-title":"Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia","volume":"25","author":"Anand","year":"1995","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ccl.2008.01.001_bib131","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ccl.2008.01.001_bib132","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccl.2008.01.001_bib133","doi-asserted-by":"crossref","unstructured":"Ghali JK, Anand IS, Abraham WT, et\u00a0al. Randomized Double-Blind Trial of Darbepoetin alfa in Patients With Symptomatic Heart Failure and Anemia. Circulation. January 14, 2008; [epub ahead of print].","DOI":"10.1161\/CIRCULATIONAHA.107.698514"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865108000027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865108000027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T22:53:29Z","timestamp":1557788009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865108000027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":133,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0733865108000027"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2008.01.001","relation":{},"ISSN":["0733-8651"],"issn-type":[{"value":"0733-8651","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}